Observational Study
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Jul 6, 2024; 12(19): 3845-3853
Published online Jul 6, 2024. doi: 10.12998/wjcc.v12.i19.3845
Prognostic role of the stromal cell derived factor-1 in patients with hepatitis B virus-related acute-on-chronic liver failure
Li Zhang, Jian-Yu Wang, Cai-Yan Zhao, Chuan Shen, Mei-Ru Chen, Zhi-Ying Tian
Li Zhang, Mei-Ru Chen, Zhi-Ying Tian, Department of Gastroenterology, Hengshui People's Hospital, Hengshui 053000, Hebei Province, China
Jian-Yu Wang, Department of Neurology, Hengshui People's Hospital, Hengshui 053000, Hebei Province, China
Cai-Yan Zhao, Chuan Shen, Department of Infection, The Third Affiliated Hospital of Hebei Medical University, Shijiazhuang 050000, Hebei Province, China
Author contributions: Tian ZY designed the study; Wang JY, Zhao CY, Shen C, Chen MR performed the data collection and analysed the data; and Zhang L wrote the manuscript; All authors reviewed the manuscript.
Supported by Science and Technology Project of Hengshui, No. 2019014061Z.
Institutional review board statement: This study was reviewed by the Ethics Committee of the Third Affiliated Hospital of Hebei Medical University, 2021-3-021.
Informed consent statement: The study exclusively utilized anonymized patient data, ensuring no invasion of personal privacy. All patient data were collected, recorded, and managed strictly for research purposes within this study, posing no risk to the participants. Consequently, the ethics committee of the Third Affiliated Hospital of Hebei Medical University has granted a waiver for informed consent.
Conflict-of-interest statement: All authors declare that there is no conflict of interest in this study.
Data sharing statement: Please contact the corresponding author for original data.
STROBE statement: The authors have read the STROBE Statement—checklist of items, and the manuscript was prepared and revised according to the STROBE Statement—checklist of items.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Zhi-Ying Tian, MD, Associate Chief Physician, Department of Gastroenterology, Hengshui People's Hospital, No. 180 Renmin East Road, Hengshui 053000, Hebei Province, China. hshy2024@163.com
Received: March 9, 2024
Revised: May 7, 2024
Accepted: May 13, 2024
Published online: July 6, 2024
Processing time: 111 Days and 23.3 Hours
Abstract
BACKGROUND

Stromal cell derived factor-1 (SDF-1) plays a pivotal role in the recruitment of stem cells to injured livers. However, the changes of SDF-l in patients with hepatitis B virus (HBV)-related acute-on-chronic liver failure (ACLF) have yet to be elucidated.

AIM

To study the SDF-1 changes in patients with HBV-related ACLF.

METHODS

30 patients with HBV-related ACLF, 27 patients with chronic hepatitis B and 20 healthy individuals are involved in our study. The SDF-l mRNA expression in liver tissue was detected by quantitative real-time polymerase chain reaction. Immunohistochemical staining was performed to illustrate the expression of SDF-l, CXC receptor 4 (CXCR4) and Ki67. The serum SDF-l concentrations were also detected by enzyme-linked immunosorbent assays.

RESULTS

The expression of SDF-1 mRNA from ACLF patients was remarkably higher than that from other patients (both P < 0.05). The expression of SDF-l, CXCR4 and Ki67 from ACLF were the highest among the three groups (all P < 0.01). The serum SDF-l levels in ACLF patients were significantly lower than that in other patients (both P < 0.01). Moreover, in ACLF patients, the serum SDF-1 Levels were positively correlated with serum total bilirubin and international normalized ratio. In addition, the serum SDF-l levels in survival were significantly lower compared with the non-survivals (P < 0.05). The area under the curve for the serum SDF-1 level in predicting 28-d mortality was 0.722 (P < 0.05).

CONCLUSION

This study provides the SDF-1 changes in patients with HBV-related ACLF. The SDF-1 Level at admission may serve as a promising prognostic marker for predicting short-term prognosis.

Keywords: Stromal cell derived factor-1; CXC receptor 4; Acute-on-chronic liver failure; Hepatitis B; Prognosis

Core Tip: In this study, we investigated the changes in stromal cell derived factor-1 (SDF-1) in hepatitis B virus (HBV) associated acute-on-chronic liver failure (ACLF) patients. 30 HBV related ACLF patients, 27 chronic hepatitis B patients, and 20 healthy participants participated in our study. Our research findings provide information on the changes in SDF-1 in HBV associated ACLF patients. The level of SDF-1 at admission can serve as a promising prognostic marker for predicting short-term prognosis.